IL6 and in situ carcinoma: The use of CIS in cancer therapy is usually accompanied by inflammation [65] and increased pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), inducible nitric oxide synthase (iNOS), interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6) [28,66,67].